{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:12:37Z","timestamp":1791839557324,"version":"4.3.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Biocodex","award":["Biocodex"],"award-info":[{"award-number":["Biocodex"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Treatment recommendations for urea cycle disorders (UCDs) include supplementation with amino acids involved in the urea cycle (arginine and\/or citrulline, depending on the enzyme deficiency), to maximize ammonia excretion through the urea cycle, but limited data are available regarding the use of citrulline. This study retrospectively reviewed clinical and biological data from patients with UCDs treated with citrulline and\/or arginine at a reference center since 1990. The aim was to describe the prescription, impact, and safety of these therapies. Data collection included patient background, treatment details, changes in biochemical parameters (plasma ammonia and amino acids concentrations), decompensations, and patient outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 79 patients (median age at diagnosis, 0.9 months) received citrulline and\/or arginine in combination with a restricted protein diet, most with ornithine transcarbamylase (n\u2009=\u200957, 73%) or carbamoyl phosphate synthetase 1 (n\u2009=\u200915, 19%) deficiencies. Most patients also received ammonium scavengers. Median follow-up was 9.5 years and median exposure to first treatment with arginine\u2009+\u2009citrulline, citrulline monotherapy, or arginine monotherapy was 5.5, 2.5, or 0.3 years, respectively. During follow-up, arginine or citrulline was administered at least once (as monotherapy or in combination) in the same proportion of patients (86.1%); the overall median duration of exposure was 5.9 years for arginine\u2009+\u2009citrulline, 3.1 years for citrulline monotherapy, and 0.6 years for arginine monotherapy. The most common switch was from monotherapy to combination therapy (41 of 75 switches, 54.7%). During treatment, mean ammonia concentrations were 35.9 \u00b5mol\/L with citrulline, 49.8 \u00b5mol\/L with arginine, and 53.0 \u00b5mol\/L with arginine\u2009+\u2009citrulline. Mean plasma arginine concentrations increased significantly from the beginning to the end of citrulline treatment periods (from 67.6 \u00b5mol\/L to 84.9 \u00b5mol\/L, P\u2009&lt;\u20090.05). At last evaluation, mean height and weight for age were normal and most patients showed normal or adapted behavior (98.7%) and normal social life (79.0%). Two patients (2.5%) experienced three treatment-related gastrointestinal adverse reactions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study underlines the importance of citrulline supplementation, either alone or together with arginine, in the management of patients with UCDs. When a monotherapy is considered, citrulline would be the preferred option in terms of increasing plasma arginine concentrations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-023-02800-8","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T12:02:01Z","timestamp":1689940921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Citrulline in the management of patients with urea cycle disorders"],"prefix":"10.1186","volume":"18","author":[{"given":"Apolline","family":"Imbard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Bouchereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Baptiste","family":"Arnoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Brassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire-Marine","family":"B\u00e9rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Pontoizeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Benoist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constant","family":"Josse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Montestruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2971-726X","authenticated-orcid":false,"given":"Pascale","family":"de Lonlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"2800_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1750-1172-7-32","volume":"7","author":"J H\u00e4berle","year":"2012","unstructured":"H\u00e4berle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2800_CR2","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/jimd.12100","volume":"42","author":"J H\u00e4berle","year":"2019","unstructured":"H\u00e4berle J, Burlina A, Chakrapani A, Dixon M, Karall D, Lindner M, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. J Inherit Metab Dis. 2019;42(6):1192\u2013230.","journal-title":"J Inherit Metab Dis"},{"key":"2800_CR3","doi-asserted-by":"publisher","first-page":"632307","DOI":"10.3389\/fneur.2021.632307","volume":"12","author":"K Sen","year":"2021","unstructured":"Sen K, Anderson AA, Whitehead MT, Gropman AL. Review of multi-modal imaging in urea cycle disorders: the old, the new, the borrowed, and the blue. Front Neurol. 2021;12:632307.","journal-title":"Front Neurol"},{"key":"2800_CR4","doi-asserted-by":"publisher","first-page":"114343","DOI":"10.1016\/j.ab.2021.114343","volume":"636","author":"K Sen","year":"2022","unstructured":"Sen K, Whitehead M, Castillo Pinto C, Caldovic L, Gropman A. Fifteen years of urea cycle disorders brain research: looking back, looking forward. Anal Biochem. 2022;636:114343.","journal-title":"Anal Biochem"},{"key":"2800_CR5","unstructured":"Fili\u00e8re de sant\u00e9 Maladies Rares G2M. Protocole National de Diagnostic et de Soins (PNDS): D\u00e9ficits du cycle de l\u2019ur\u00e9e. 2021. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-06\/pnds_ucd_vf.pdf Accessed 2 June 2022."},{"key":"2800_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-015-0266-1","volume":"10","author":"A Brassier","year":"2015","unstructured":"Brassier A, Gobin S, Arnoux JB, Valayannopoulos V, Habarou F, Kossorotoff M, et al. Long-term outcomes in ornithine transcarbamylase deficiency: a series of 90 patients. Orphanet J Rare Dis. 2015;10:58.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2800_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/ped.13163","volume":"59","author":"K Tanaka","year":"2017","unstructured":"Tanaka K, Nakamura K, Matsumoto S, Kido J, Mitsubuchi H, Ohura T, et al. Citrulline for urea cycle disorders in Japan. Pediatr Int. 2017;59(4):422\u20136.","journal-title":"Pediatr Int"},{"issue":"1\u20132","key":"2800_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ymgme.2019.07.009","volume":"128","author":"GM Enns","year":"2019","unstructured":"Enns GM, Porter MH, Francis-Sedlak M, Burdett A, Vockley J. Perspectives on urea cycle disorder management: results of a clinician survey. Mol Genet Metab. 2019;128(1\u20132):102\u20138.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"2800_CR9","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.jpeds.2013.08.029","volume":"163","author":"PJ McGuire","year":"2013","unstructured":"McGuire PJ, Lee HS, members of the Urea Cycle Disorders C, Summar ML. Infectious precipitants of acute hyperammonemia are associated with indicators of increased morbidity in patients with urea cycle disorders. J Pediatr. 2013;163(6):1705\u201310e1.","journal-title":"J Pediatr"},{"issue":"10","key":"2800_CR10","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/j.1651-2227.2008.00952.x","volume":"97","author":"ML Summar","year":"2008","unstructured":"Summar ML, Dobbelaere D, Brusilow S, Lee B. Diagnosis, symptoms, frequency and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre study of acute hyperammonaemic episodes. Acta Paediatr. 2008;97(10):1420\u20135.","journal-title":"Acta Paediatr"},{"key":"2800_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ymgmr.2016.07.003","volume":"8","author":"OA Shchelochkov","year":"2016","unstructured":"Shchelochkov OA, Dickinson K, Scharschmidt BF, Lee B, Marino M, Le Mons C. Barriers to drug adherence in the treatment of urea cycle disorders: assessment of patient, caregiver and provider perspectives. Mol Genet Metab Rep. 2016;8:43\u20137.","journal-title":"Mol Genet Metab Rep"},{"issue":"4","key":"2800_CR12","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/jimd.12384","volume":"44","author":"J Kido","year":"2021","unstructured":"Kido J, Matsumoto S, H\u00e4berle J, Nakajima Y, Wada Y, Mochizuki N, et al. Long-term outcome of urea cycle disorders: report from a nationwide study in Japan. J Inherit Metab Dis. 2021;44(4):826\u201337.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2800_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-2125.2007.02990.x","volume":"65","author":"E Schwedhelm","year":"2008","unstructured":"Schwedhelm E, Maas R, Freese R, Jung D, Lukacs Z, Jambrecina A, et al. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol. 2008;65(1):51\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2800_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1017\/S0007114515004638","volume":"115","author":"C Moinard","year":"2016","unstructured":"Moinard C, Maccario J, Walrand S, Lasserre V, Marc J, Boirie Y, et al. Arginine behaviour after arginine or citrulline administration in older subjects. Br J Nutr. 2016;115(3):399\u2013404.","journal-title":"Br J Nutr"},{"issue":"10 Suppl","key":"2800_CR15","doi-asserted-by":"publisher","first-page":"2791S","DOI":"10.1093\/jn\/134.10.2791S","volume":"134","author":"ME Brosnan","year":"2004","unstructured":"Brosnan ME, Brosnan JT. Renal arginine metabolism. J Nutr. 2004;134(10 Suppl):2791S\u20135S.","journal-title":"J Nutr"},{"issue":"6","key":"2800_CR16","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/jimd.12066","volume":"42","author":"F Molema","year":"2019","unstructured":"Molema F, Gleich F, Burgard P, van der Ploeg AT, Summar ML, Chapman KA, et al. Evaluation of dietary treatment and amino acid supplementation in organic acidurias and urea-cycle disorders: on the basis of information from a european multicenter registry. J Inherit Metab Dis. 2019;42(6):1162\u201375.","journal-title":"J Inherit Metab Dis"},{"issue":"6 Suppl 2","key":"2800_CR17","doi-asserted-by":"publisher","first-page":"1646S","DOI":"10.1093\/jn\/137.6.1646S","volume":"137","author":"L Cynober","year":"2007","unstructured":"Cynober L. Pharmacokinetics of arginine and related amino acids. J Nutr. 2007;137(6 Suppl 2):1646S\u20139S.","journal-title":"J Nutr"},{"issue":"9","key":"2800_CR18","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s00431-006-0143-y","volume":"165","author":"H Nagasaka","year":"2006","unstructured":"Nagasaka H, Yorifuji T, Murayama K, Kubota M, Kurokawa K, Murakami T, et al. Effects of arginine treatment on nutrition, growth and urea cycle function in seven japanese boys with late-onset ornithine transcarbamylase deficiency. Eur J Pediatr. 2006;165(9):618\u201324.","journal-title":"Eur J Pediatr"},{"key":"2800_CR19","doi-asserted-by":"publisher","first-page":"100724","DOI":"10.1016\/j.ymgmr.2021.100724","volume":"27","author":"J Kido","year":"2021","unstructured":"Kido J, Matsumoto S, Ito T, Hirose S, Fukui K, Kojima-Ishii K, et al. Physical, cognitive, and social status of patients with urea cycle disorders in Japan. Mol Genet Metab Rep. 2021;27:100724.","journal-title":"Mol Genet Metab Rep"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02800-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-023-02800-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-023-02800-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T12:06:01Z","timestamp":1689941161000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-023-02800-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2800"],"URL":"https:\/\/doi.org\/10.1186\/s13023-023-02800-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]},"assertion":[{"value":"7 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J-BA has acted as a consultant for Pierre Fabre Medicament. The remaining authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research was conducted according to the principles of the Declaration of Helsinki and local and international laws. As this was a retrospective study no regulatory approval or written informed consent was required. A declaration of compliance with reference methodology MR-004 (which governs the processing of personal data in the context of research not involving human subjects) was sent to the Commission Nationale de l\u2019Informatique et des Libert\u00e9s (CNIL), and all data were processed in accordance with this methodology. In accordance with the regulations applicable to the processing of personal data and European Regulation 2016\/679 of 27 April 2016, BIOCODEX was the sole controller of the processing of the data collected during this research. A written note informing the patients of the use of their data was sent by post or given at a regular consultation. This note included the purpose of the research and the data to be collected, as well as the patient\u2019s right to refuse the use of their medical data, without any consequences for their usual care. The methods for the patient to express opposition were also described. In the event of a death of the patient involved in the research, the investigator ensured that the patient had not objected in writing to the use of their personal data during their lifetime. If the patient had objected in writing, their data were not included in the research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"207"}}